Human Genome Epidemiology Literature Finder
Records 1 - 5 (of 5 Records) |
Query Trace: Vomiting and CYP2A6[original query] |
---|
Population pharmacokinetic analysis of letrozole in Japanese postmenopausal women. European journal of clinical pharmacology 2011 Oct 67 (10): 1017-25. Tanii Hiromi, Shitara Yoshihisa, Horie Toshiha |
Phase II study of S-1 combined with oxaliplatin as therapy for patients with metastatic biliary tract cancer: influence of the CYP2A6 polymorphism on pharmacokinetics and clinical activity. British journal of cancer 2011 Feb 104 (4): 605-12. Kim K-p, Jang G, Hong Y S, Lim H-S, Bae K-s, Kim H-S, Lee S S, Shin J-G, Lee J-L, Ryu M-H, Chang H-M, Kang Y-K, Kim T |
S-1 plus irinotecan and oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: a prospective phase II study and pharmacogenetic analysis. British journal of cancer 2013 Sep 109 (6): 1420-7. Kim S Y, S Hong Y, K Shim E, Kong S-Y, Shin A, Baek J Y, Jung K |
[Validation of genetic polymorphisms associated to the toxicity of chemotherapy in colorectal cancer patients]. Farmacia hospitalaria : órgano oficial de expresión científica de la Sociedad Española de Farmacia Hospitalaria 0 38 (4): 283-90. Cortejoso L, García M I, García-Alfonso P, Grávalos C, Robles L, González-Haba E, Sanjurjo M, López-Fernández L |
A randomized phase II study of S-1 versus capecitabine as first-line chemotherapy in elderly metastatic gastric cancer patients with or without poor performance status: clinical and pharmacogenetic results. Pharmacogenetics and genomics 2017 Nov . Kim Mi-Jung, Kong Sun-Young, Nam Byung-Ho, Kim Sohee, Park Young-Iee, Park Sook Ry |
- Page last reviewed:Feb 1, 2024
- Page last updated:Mar 25, 2024
- Content source: